selected scholarly activity
-
chapters
-
conferences
- A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A). Journal of Clinical Oncology. 2023
- Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial. Journal of Clinical Oncology. 2023
- Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.. Journal of Clinical Oncology. 2022
- Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.. Journal of Clinical Oncology. 2022
- MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. S291-S292. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. v179-v179. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. 2019
- CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).. Journal of Clinical Oncology. 3512-3512. 2019
- CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).. Journal of Clinical Oncology. 481-481. 2019
- How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience. Annals of Oncology. viii568-viii568. 2018
- MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience. Journal of Thoracic Oncology. S419-S419. 2018
- P2.11-23 Risk Perception Among a Lung Cancer Screening Population. Journal of Thoracic Oncology. S788-S788. 2018
- A Randomized Phase Ii Trial of Selumetinib plus Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219. Journal of Thoracic Oncology. S2080-S2080. 2017
- MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. Journal of Thoracic Oncology. S1839-S1839. 2017
- MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population. Journal of Thoracic Oncology. S1890-S1890. 2017
- OA 06.01 Costs and Cost-Effectiveness of Smoking Cessation Within an Organized CT Lung Cancer (LC) Screening Program. Journal of Thoracic Oncology. S1757-S1758. 2017
- OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study. Journal of Thoracic Oncology. S1784-S1785. 2017
- A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC).. Journal of Clinical Oncology. e20019-e20019. 2017
- Use of a marketing plan for recruitment to a lung cancer screening study.. Journal of Clinical Oncology. 1548-1548. 2017
- MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study. Journal of Thoracic Oncology. S366-S367. 2017
- OA17.02 Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada. Journal of Thoracic Oncology. S309-S309. 2017
- Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. Chest. 547A-547A. 2015
- A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial. Journal of Thoracic Oncology. S352-S352. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 8046-8046. 2015
- BIENNIAL LUNG CANCER SCREENING BY LOW-DOSE CT SCAN - A SIMULATION OF COST EFFECTIVENESS IN CANADA. Journal of Thoracic Oncology. S149-S149. 2013
- BIOMARKER ANALYSIS OF NCIC CLINICAL TRIALS GROUP IND.196, A PHASE I STUDY OF ERLOTINIB PLUS FORETINIB IN ADVANCED PRETREATED NON-SMALL CELL LUNG CANCER PATIENTS. Journal of Thoracic Oncology. S330-S331. 2013
- EDUCATING COMMUNITY HEALTH PROFESSIONALS ABOUT LUNG CANCER: A PILOT EVALUATION OF A WEB-BASED EDUCATIONAL TOOL. Journal of Thoracic Oncology. S873-S874. 2013
- FACTORS ASSOCIATED WITH SMOKING CESSATION IN PARTICIPANTS OF THE PAN CANADIAN EARLY LUNG CANCER STUDY. Journal of Thoracic Oncology. S155-S156. 2013
- RESOURCE UTILIZATION IN THE LAST THREE MONTHS OF LIFE BY LUNG CANCER PATIENTS IN THE HAMILTON-NIAGARA-HALDIMAND-BRANT LOCAL HEALTH INTEGRATION NETWORK (LHIN). Journal of Thoracic Oncology. S213-S213. 2013
- Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada. Journal of Clinical Oncology. 2013
- 607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. European Journal of Cancer. 187-187. 2012
- NCIC CTG IND.196: PHASE I STUDY OF FORETINIB (GSK1363089) AND ERLOTINIB IN PATIENTS WITH ADVANCED PRETREATED NSCLC. Journal of Thoracic Oncology. S453-S453. 2012
- PRIMARY MALIGNANT BRAIN TUMORS IN THE ELDERLY: RETROSPECTIVE ANALYSIS OF MANAGEMENT AND OUTCOME. Neuro-Oncology. 42-42. 2012
- STRATIFICATION ACCORDING TO HGG-IMMUNO RPA MODEL PREDICTS OUTCOME IN PATIENTS WITH RELAPSED MALIGNANT GLIOMA TREATED BY ADJUVANT POSTOPERATIVE DC VACCINATION. Neuro-Oncology. 60-60. 2012
- A PHASE II STUDY EVALUATING CONCURRENT PEMETREXED/CISPLATIN/RADIATION (RT) FOR UNRESECTABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC). Journal of Thoracic Oncology. S1543-S1544. 2011
- DO BETA-BLOCKERS ALTER DYSPNEA AND FATIGUE IN ADVANCED LUNG CANCER? A RETROSPECTIVE ANALYSIS. Journal of Thoracic Oncology. S1192-S1193. 2011
- PULMONARY FUNCTION AS A PREDICTOR OF LUNG CANCER RISK. Journal of Thoracic Oncology. S349-S350. 2011
- Canadian cancer risk management model: A new health policy tool useful in policy decisions related to lung cancer.. Journal of Clinical Oncology. e16541-e16541. 2011
- Impact of increased use of adjuvant chemotherapy in non-small cell lung cancer: A population and economic assessment.. Journal of Clinical Oncology. e16630-e16630. 2011
- EPENDYMOMAS OF THE FILUM TERMINALE: A SINGLE-INSTITUTION EXPERIENCE. Neuro-Oncology. 55-55. 2010
- IMMUNOTHERAPY INTEGRATED IN RADIOCHEMOTHERAPY AND MAINTENANCE TENIOZOLOMIDE: FINAL RESULTS OF THE HGG-2006 STUDY. Neuro-Oncology. II13-II13. 2010
- Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials.. Journal of Clinical Oncology. e13004-e13004. 2010
- Individualized patient care: Are we ready to meet the challenges for patients with lung cancer?. Journal of Clinical Oncology. e18121-e18121. 2010
- INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GLIOBLASTOMA: FINAL RESULTS OF THE HGG-2006 PHASE I/II TRIAL. Neuro-Oncology. 612-612. 2009
- VALIDATION OF RPA CLASSIFICATION AS A PROGNOSTIC TOOL IN ADULT PATIENTS WITH RELAPSED HIGH-GRADE GLIOMA VACCINATED AT TIME OF RECURRENCE. Neuro-Oncology. 612-612. 2009
- Evaluation of the deliverability and tolerability of intensive weekly doublet adjuvant chemotherapy in Non Small Cell Lung Cancer. Journal of Thoracic Oncology. S787-S787. 2009
- Priority health needs for patients receiving concurrent chemotherapy and radiation for stage III non-small cell lung cancer and impact of the role of the advanced practice nurse (APN). Journal of Thoracic Oncology. S436-S437. 2009
- Survival of patients with non small cell lung cancer (NSCLC) following diagnosis of brain metastases. Journal of Thoracic Oncology. S543-S544. 2009
- The pan-Canadian early detection of lung cancer study. Journal of Thoracic Oncology. S377-S378. 2009
- Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GBM: UPDATE OF THE HGG-2006 PHASE I/II TRIAL. Neuro-Oncology. 812-812. 2008
- Phase II stopping rules employing response rates and early progression. Journal of Clinical Oncology. 2007
- Imaging findings related to adjuvant dendritic cell (DC) vaccination in patients with relapsed high-grade glioma. Neuro-Oncology. 351-351. 2006
- BRCA1 germ-line mutation status, distinctive cell cycle proteins expression and outcome after breast cancer.. American Journal of Human Genetics. 231-231. 2003
- Good response to chemotherapy (CT) and hormonotherapy (HT) in patients with BRCA1-related breast cancer (BRCA1-BC).. American Journal of Human Genetics. 249-249. 2001
-
journal articles
- Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.. Journal for ImmunoTherapy of Cancer. 12:e010094. 2024
- Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".. Journal of Thoracic Oncology. 19:1578-1579. 2024
- Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.. Journal of Clinical Oncology. 42:3587-3587. 2024
- Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer. JAMA network open. 6:e2346094-e2346094. 2023
- Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. The Lancet. 402:2295-2306. 2023
- A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).. Journal of Clinical Oncology. 41:TPS2673-TPS2673. 2023
- Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). Journal of Thoracic Oncology. 18:813-819. 2023
- Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. Journal of Clinical Oncology. 41:3545-3545. 2023
- Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. Journal of Clinical Oncology. 41:183-183. 2023
- Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 15:17588359231183682. 2023
- Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.. Journal of Clinical Oncology. 40:3600-3600. 2022
- Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.. Journal of Clinical Oncology. 40:e21172-e21172. 2022
- A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer. BMC Cancer. 21:14. 2021
- Risk Perception Among a Lung Cancer Screening Population. Chest. 160:718-730. 2021
- Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 151:108-109. 2021
- Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. PLoS ONE. 16:e0251886-e0251886. 2021
- Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. BMC Pulmonary Medicine. 20:300. 2020
- Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. CMAJ open. 8:E585-E592. 2020
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. JAMA Oncology. 6:831-831. 2020
- A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer. 143:1-11. 2020
- Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. Clinical Trials. 17:202-211. 2020
- Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. Frontiers in Oncology. 10:575148. 2020
- Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario. Current Oncology. 26:247-252. 2019
- Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. Lung Cancer. 133:48-55. 2019
- Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Investigational New Drugs. 37:498-506. 2019
- Initial Management of Small-Cell Lung Cancer (limited- and Extensive-Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy: A Systematic Review. Current Oncology. 26:372-384. 2019
- Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. BMJ Open. 9:e024719-e024719. 2019
- Cost-Effectiveness of Smoking Cessation Within a Lung Cancer Screening Program in Canada. Journal of Global Oncology. 4:41s-41s. 2018
- Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy. Clinical Oncology. 30:658-666. 2018
- Lung Cancer–Related Clinical and Economic Impacts of Achieving a 5% Smoking Prevalence Rate by 2035 in Canada. Journal of Global Oncology. 4:28s-28s. 2018
- A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clinical Colorectal Cancer. 17:231-239.e7. 2018
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer. 120:142-148. 2018
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167:485-493. 2018
- P2.01-032 A Randomized Phase Ii Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219. Journal of Thoracic Oncology. 12:S2081-S2081. 2017
- Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. The Lancet Oncology. 18:1523-1531. 2017
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget. 8:69651-69662. 2017
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.. Oncotarget. 8:69651-69662. 2017
- The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology. 12:1210-1222. 2017
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 104:65-69. 2017
- American Society of Clinical Oncology Policy Brief: FDA’s Regulation of Electronic Nicotine Delivery Systems and Tobacco Products. JCO Oncology Practice. 13:58-60. 2017
- A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology. 11:2018-2021. 2016
- Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness. Lung Cancer. 101:98-103. 2016
- Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. Chest. 150:1015-1022. 2016
- “Plasma pro-surfactant protein B and lung function decline in smokers.” Janice M. Leung, John Mayo, Wan Tan, C. Martin Tammemagi, Geoffrey Liu, Stuart Peacock, Frances A. Shepherd, John Goffin, Glenwood Goss, Garth Nicholas, Alain Tremblay, Michael Johnston, Simon Martel, Francis Laberge, Rick Bhatia, Heidi Roberts, Paul Burrowes, Daria Manos, Lori Stewart, Jean M. Seely, Michel Gingras, Sergio Pasian, Ming-Sound Tsao, Stephen Lam and Don D. Sin, for the Pan-Canadian Early Lung Cancer Study Group.Eur Respir J2015; 45: 1037–1045.. European Respiratory Journal. 48:962.2-962. 2016
- Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. Current Oncology. 23:179-187. 2016
- A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.. Journal of Clinical Oncology. 34:e20512-e20512. 2016
- IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 34:3546-3546. 2016
- Lung Cancer Screening, Cancer Treatment, and Addressing the Continuum of Health Risks Caused by Tobacco. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 35:223-229. 2016
- Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17:133-141. 2016
- Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply. JAMA Oncology. 2:278-278. 2016
- Lung Cancer Screening, Cancer Treatment, and Addressing the Continuum of Health Risks Caused by Tobacco. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 36:223-229. 2016
- Perspective on the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines for Smoking Cessation. Journal of Oncology Practice. 12:55-58. 2016
- Cost-effectiveness of Lung Cancer Screening in Canada. JAMA Oncology. 1:807-807. 2015
- Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. Current Oncology. 22:272-278. 2015
- Performance of the cancer risk management model lung cancer screening module. Health Reports. 26:11-18. 2015
- Plasma pro-surfactant protein B and lung function decline in smokers. European Respiratory Journal. 45:1037-1045. 2015
- Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology. 9:1449-1458. 2014
- Assessment of a dyspnea clinic for patients with thoracic malignancies.. Journal of Clinical Oncology. 32:e20667-e20667. 2014
- Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. New England Journal of Medicine. 369:910-919. 2013
- Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics. 35:1282-1303. 2013
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. Current Oncology. 20:300-306. 2013
- A Comparison of Patient Knowledge of Clinical Trials and Trialist Priorities. Current Oncology. 20:193-205. 2013
- Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada.. Journal of Clinical Oncology. 31:6550-6550. 2013
- CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROL. International Journal of Technology Assessment in Health Care. 29:131-139. 2013
- Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunology, Immunotherapy. 61:2105-2112. 2012
- Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis. Palliative Medicine. 26:797-803. 2012
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs. 30:1203-1207. 2012
- The Evaluation of Cancer Control Interventions in Lung Cancer using the Canadian Cancer Risk Management Model. Lung Cancer Management. 1:25-33. 2012
- A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. BMC Medical Research Methodology. 11:95. 2011
- Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. BMC Medical Research Methodology. 11:164. 2011
- Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. Journal of Thoracic Oncology. 6:1950-1954. 2011
- Early stopping rules in oncology: Considerations for clinicians. European Journal of Cancer. 47:2381-2386. 2011
- Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. Journal of Neuro-Oncology. 99:261-272. 2010
- First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. 5:260-274. 2010
- In Reply. Journal of Clinical Oncology. 27:647-647. 2009
- Phase II Stopping Rules That Employ Response Rates and Early Progression. Journal of Clinical Oncology. 26:3715-3720. 2008
- Phase II stopping rules employing response rates and early progression. Journal of Clinical Oncology. 25:2553-2553. 2007
- Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer. Journal of Clinical Oncology. 24:528-529. 2006
- Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval. Clinical Cancer Research. 11:5928-5934. 2005
- Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Annals of Oncology. 16:735-742. 2005
- Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 11:3417-3424. 2005
- DEALE-ing with Lung Cancer and Heart Failure. Medical decision making. 25:82-94. 2005
- The difference between study recommendations, stated policy, and actual practice in a clinical trial. Annals of Oncology. 15:1267-1273. 2004
- Tolerance of Radiotherapy and Chemotherapy in Elderly Patients With Bladder Cancer. American Journal of Clinical Oncology. 27:172-177. 2004
- The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1 -Related Breast Cancer. Cancer Research. 64:830-835. 2004
- A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research. 6:R8-R17. 2004
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. Journal of the National Cancer Institute. 95:1482-1485. 2003
- Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. British Journal of Cancer. 89:1031-1034. 2003
- Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma. Cancer. 97:527-536. 2003
- Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.. Cancer Research. 62:6808-6811. 2002
- DNA methyltransferase inhibitors—state of the art. Annals of Oncology. 13:1699-1716. 2002
- Tamoxifen May Be an Effective Adjuvant Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status. Journal of the National Cancer Institute. 94:1504-1506. 2002
- A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. Journal of Medical Genetics. 39:608-610. 2002
- Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines. Current Oncology. 9:7-12. 2002
- Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer. Journal of the National Cancer Institute. 93:1754-1754. 2001
- Bleomycin-Induced Lung Toxicity and Pentoxifylline. Journal of Clinical Oncology. 19:597-598. 2001